How close are we to CAR T-cell therapy for AML?

Chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has thus far been elusive, in part owing to the absence of truly AML-specific surface antigens, making AML difficult to target. However, progress has been made toward the use of CAR T-cell therapy in this disease, prompt...

Full description

Saved in:
Bibliographic Details
Published inBest practice & research. Clinical haematology Vol. 32; no. 4; p. 101104
Main Author Gill, Saar I.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.12.2019
Subjects
Acute myeloid leukemia
Allografts
AML
CAR
CART
CD123
CD33
Chimeric antigen receptor
Chimeric antigen receptor T cell
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy, Adoptive
Leukemia, Myeloid, Acute - therapy
Receptors, Chimeric Antigen - therapeutic use
Transplantation Conditioning
AML
Chimeric antigen receptor T cell
Chimeric antigen receptor
CAR
Acute myeloid leukemia
CD33
CD123
CART
Online AccessGet full text

Cover

More Information
Summary:Chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has thus far been elusive, in part owing to the absence of truly AML-specific surface antigens, making AML difficult to target. However, progress has been made toward the use of CAR T-cell therapy in this disease, prompting the topic of this paper. Discussion and clinical examples of potential solutions to creating a safe and effective CAR T cell for AML include: (1) Decreasing the potency or activity of CAR T cells to enhance the therapeutic window; (2) Using transient or depletable CAR T cells as part of pre-transplant conditioning; and (3) Using a gene-edited allogeneic donor hematopoietic stem cell transplant in order to allow safe and protracted anti-AML CAR T-cell function.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1521-6926
1532-1924
DOI:10.1016/j.beha.2019.101104